Last edition
News about "Merck"
Merck Launches ChemiSphere App to Streamline Digital Data Access and Enhance Lab Efficiency
Merck has launched the ChemiSphere app to streamline digital data access and improve lab efficiency by linking physical products with secure digital workflows, enabling quick access to key documentation such as SDS and CoA.
Merck | 17/12/2025 | By News Bureau
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Merck | 15/11/2025 | By Dineshwori | 185
Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion
Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.
Merck | 14/11/2025 | By Darshana
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Merck | 29/10/2025 | By Dineshwori | 131
Merck KGaA Reports Sustained Efficacy and Safety of OGSIVEO in Phase-III Desmoid Tumour Study
Merck KGaA has released long-term phase-III data showing that OGSIVEO treatment for up to four years continues to deliver durable tumour reductions, improved response rates, sustained symptom relief, and a consistent safety profile in patients with desmoid tumours.
Merck | 27/10/2025 | By Dineshwori | 124
Merck Commits More Than USD 70 Billion to USA Manufacturing and R&D Expansion
A central component of this investment is the construction of a USD 3 billion pharmaceutical manufacturing facility in Elkton, Virginia, which is expected to generate around 500 permanent jobs and several thousand construction roles.
Merck | 21/10/2025 | By Darshana | 176
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Merck | 13/10/2025 | By Dineshwori | 187
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Merck | 11/10/2025 | By Dineshwori | 681
Merck Completes Acquisition of Verona Pharma
The acquisition of Verona Pharma strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade.
Merck | 08/10/2025 | By Dineshwori | 101
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Merck | 07/10/2025 | By Dineshwori | 276
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy